Idorsia Pharmaceuticals Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Allschwil Switzerland (2017)

Organization Overview

First Clinical Trial
2017
NCT03245229
First Marketed Drug
2022
daridorexant (Quviviq)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Idorsia Pharmaceuticals | Idorsia Pharmaceuticals Ltd. | IDORSIA PHARMACEUTICALS LTD. | Idosia Pharmaceuticals Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Apnea (Phase 1)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Epilepsy (Phase 2)

Epilepsy, Reflex (Phase 2)

Fabry Disease (Phase 3)

Hemorrhage (Phase 3)

Hypertension (Phase 3)

Infarction (Phase 2)

Kidney Diseases (Phase 3)

Liver Diseases (Phase 1)

Lung Diseases (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Lupus Erythematosus, Systemic (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

Nasal Polyps (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Sleep Apnea, Obstructive (Phase 1)

Sleep Apnea Syndromes (Phase 1)

Sleep Initiation and Maintenance Disorders (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 62
  • # of Trial APIs: 41